OSUR — OraSure Technologies, Inc.

Is OSUR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Oversold As of August 19, 2026

OraSure Technologies, Inc. (OSUR) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $3.75. The rating moved from Neutral to Oversold on August 15, 2026.

See all oversold Healthcare stocks →

AI analysis

OraSure Technologies, Inc. (OSUR) operates in established sample-collection and point-of-care diagnostics niches with a mix of recurring revenue and product-led opportunities. Near-term performance will be driven by stabilization of testing demand post-pandemic, reimbursement dynamics, and execution on partnerships or new screening use cases; sector-level interest in diagnostics and screening provides a constructive backdrop but competition and regulatory/reimbursement headwinds create meaningful execution risk. Financial and operational discipline, plus successful commercialization of new indications or channel expansion, are key catalysts that would materially improve the outlook.

Key factors

  • Position in point-of-care and sample-collection diagnostics with established products (oral-fluid collection devices, infectious disease rapid tests) that generate recurring revenue streams.
  • Sector tailwinds for population screening and diagnostics demand (oncology/CRC screening interest) that could expand addressable market and lab services demand.
  • Diversification potential via partnerships and CDx / lab-service opportunities that can leverage existing collection and diagnostic platforms.
  • Valuation reflects a modest market expectation, leaving scope for upside on execution or downside if demand normalizes; current price implies limited near-term growth expectations.
  • Operational levers: product mix optimization, cost control, and targeted commercialization could materially influence margins and free cash flow.

Risks

  • Post‑pandemic normalization in infectious-disease and OTC testing volumes could compress revenue vs. prior peak levels.
  • Reimbursement and payer pressure, including changes in coverage for screening tests and specimen-collection products, can reduce realized prices and volumes.
  • Intense competition from large diagnostics companies and emerging entrants with broader test portfolios and distribution networks.
  • Concentration risk in product lines or customers and potential single-product revenue volatility.
  • Regulatory and clinical risk for any new test launches or expanded indications; delays or negative outcomes would harm growth projections.
  • Balance-sheet and financing risk: smaller-cap diagnostics firms may need capital infusions which could dilute shareholders if operating cash flow underperforms.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for OSUR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.